The use of botulinum toxin in the treatment of peripheral facial palsy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/17935 |
Resumo: | Peripheral Facial Palsy (PFP) is a state of paralysis or weakening of the facial muscles that causes motor and aesthetic limitations to the patient with this condition. One means of treatment for PFP that is gaining prominence is the use of botulinum toxin on the side contralateral to that affected by the condition. This toxin is collected from the spores of the bacterium Clostridium botulinum, and its action inhibits the release of acetylcholine at the neuromuscular junction, reducing muscle hyperfunction and restoring symmetry to the patient's face. Therefore, this study aims to achieve the knowledge of the best protocol for the application of the toxin in paralysis, as well as which serotype to use and the ability to improve the patient's quality of life. The study consists of a basic, qualitative, descriptive-exploratory integrative review based on the main research platforms searching for the terms facial paralysis and botulinum toxin. Articles were included from 2011 to 2021 in the English language and the search resulted in 17 articles. In all reviewed articles the botulinum toxin serotype A was the only one used for the treatment, the amount of biological units (BIU) and the protocol was individualized for each patient exempting from a standard. The quality of life of the patients was restored after an improvement in facial symmetry was obtained and, with this, an increase in self-esteem, besides, mainly, restoring the ability to perform coordinated muscular actions. Therefore, it can be concluded that the treatment of PFP with botulinum toxin is highly beneficial to patients. |
id |
UNIFEI_39c0ec760af21331d2a5e591ae377162 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/17935 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
The use of botulinum toxin in the treatment of peripheral facial palsyEl uso de la toxina botulínica en el tratamiento de la parálisis facial periféricaA utilização da toxina botulínica no tratamento da paralisia facial periféricaParálisis FacialSimetriaToxina botulínicaAssimetria.Facial PalsyBotulinum ToxinSymmetryAsymmetry.Paralisia FacialToxina BotulínicaSimetriaAssimetria.Peripheral Facial Palsy (PFP) is a state of paralysis or weakening of the facial muscles that causes motor and aesthetic limitations to the patient with this condition. One means of treatment for PFP that is gaining prominence is the use of botulinum toxin on the side contralateral to that affected by the condition. This toxin is collected from the spores of the bacterium Clostridium botulinum, and its action inhibits the release of acetylcholine at the neuromuscular junction, reducing muscle hyperfunction and restoring symmetry to the patient's face. Therefore, this study aims to achieve the knowledge of the best protocol for the application of the toxin in paralysis, as well as which serotype to use and the ability to improve the patient's quality of life. The study consists of a basic, qualitative, descriptive-exploratory integrative review based on the main research platforms searching for the terms facial paralysis and botulinum toxin. Articles were included from 2011 to 2021 in the English language and the search resulted in 17 articles. In all reviewed articles the botulinum toxin serotype A was the only one used for the treatment, the amount of biological units (BIU) and the protocol was individualized for each patient exempting from a standard. The quality of life of the patients was restored after an improvement in facial symmetry was obtained and, with this, an increase in self-esteem, besides, mainly, restoring the ability to perform coordinated muscular actions. Therefore, it can be concluded that the treatment of PFP with botulinum toxin is highly beneficial to patients.La parálisis facial periférica (PFP) es un estado de parálisis o debilitamiento de los músculos faciales que provoca limitaciones motoras y estéticas al paciente que la padece. Un medio de tratamiento para la PFP que ha ido ganando importancia es el uso de toxina botulínica en el lado contralateral al afectado por la afección. Esta toxina se obtiene de las esporas de la bacteria Clostridium botulinum, y actúa inhibiendo la liberación de acetilcolina en la unión neuromuscular, reduciendo la hiperfunción muscular y devolviendo la simetría al rostro del paciente. Por ello, este estudio pretende lograr el conocimiento del mejor protocolo de aplicación de la toxina en la parálisis, además de qué serotipo utilizar y la capacidad de mejorar la calidad de vida del paciente. El estudio consiste en una revisión integradora de carácter básico, cualitativo, descriptivo-explicativo basada en las principales plataformas de investigación buscando los términos parálisis facial y toxina botulínica. Se incluyeron artículos en el intervalo de tiempo de 2011 a 2021 en lengua inglesa y la búsqueda dio como resultado 17 artículos. En todos los artículos revisados la toxina botulínica serotipo A fue la única utilizada para el tratamiento, la cantidad de unidades biológicas (UBI), y el protocolo fue individualizado para cada paciente eximiendo un estándar. La calidad de vida de los pacientes fue devuelta tras obtener una mejora en la simetría facial y con ello un aumento de la autoestima, además de devolver principalmente la capacidad de realizar acciones musculares coordinadas. Por lo tanto, se puede concluir que el tratamiento de la PFP con toxina botulínica es muy beneficioso para los pacientes.A Paralisia Facial Periférica (PFP) é um estado de paralisação ou enfraquecimento dos músculos da face que causam limitações motoras e estéticas ao paciente com esta condição. Um meio de tratamento para a PFP que vem ganhando destaque é a utilização de toxina botulínica no lado contralateral ao acometido pela condição. Esta toxina é coletada através dos esporos da bactéria Clostridium botulinum, e atua inibindo a liberação de acetilcolina na junção neuromuscular, diminuindo hiperfunção muscular e devolvendo simetria a face do paciente. Portanto, este estudo tem como objetivo alcançar o conhecimento do melhor protocolo de aplicação da toxina na paralisia, além de qual sorotipo usar e a capacidade de melhoria na qualidade de vida do paciente. O estudo consta com uma revisão integrativa de caráter básico, qualitativa, descritiva-explicativa com base nas principais plataformas de pesquisa buscando os termos paralisia facial e toxina botulínica. Foram incluídos artigos no intervalo de tempo de 2011 a 2021 na língua inglesa e a busca resultou em 17 artigos. Em todos os artigos revisados o sorotipo A da toxina botulínica foi o único utilizado para o tratamento, a quantidade de unidades biológicas (UI) e o protocolo foi individualizado para cada paciente isentando de um padrão. A qualidade de vida dos pacientes foi devolvida após se obter melhora na simetria facial e com isso aumento na autoestima além de principalmente, devolver a capacidade de realizar ações musculares coordenadas. Portanto, pode-se concluir que o tratamento da PFP com toxina botulínica é altamente benéfico aos pacientes.Research, Society and Development2021-07-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1793510.33448/rsd-v10i9.17935Research, Society and Development; Vol. 10 No. 9; e8510917935Research, Society and Development; Vol. 10 Núm. 9; e8510917935Research, Society and Development; v. 10 n. 9; e85109179352525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/17935/15921Copyright (c) 2021 Mariana Martins Andalécio; Rodrigo Soares de Andrade; Luisa Carolina Santos Lima; Thiago de Amorim Carvalho; Ivania Aparecida Pimenta Santos Silvahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessAndalécio, Mariana MartinsAndrade, Rodrigo Soares de Lima, Luisa Carolina SantosCarvalho, Thiago de AmorimSilva, Ivania Aparecida Pimenta Santos2021-09-12T14:28:06Zoai:ojs.pkp.sfu.ca:article/17935Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:38:10.826341Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
The use of botulinum toxin in the treatment of peripheral facial palsy El uso de la toxina botulínica en el tratamiento de la parálisis facial periférica A utilização da toxina botulínica no tratamento da paralisia facial periférica |
title |
The use of botulinum toxin in the treatment of peripheral facial palsy |
spellingShingle |
The use of botulinum toxin in the treatment of peripheral facial palsy Andalécio, Mariana Martins Parálisis Facial Simetria Toxina botulínica Assimetria. Facial Palsy Botulinum Toxin Symmetry Asymmetry. Paralisia Facial Toxina Botulínica Simetria Assimetria. |
title_short |
The use of botulinum toxin in the treatment of peripheral facial palsy |
title_full |
The use of botulinum toxin in the treatment of peripheral facial palsy |
title_fullStr |
The use of botulinum toxin in the treatment of peripheral facial palsy |
title_full_unstemmed |
The use of botulinum toxin in the treatment of peripheral facial palsy |
title_sort |
The use of botulinum toxin in the treatment of peripheral facial palsy |
author |
Andalécio, Mariana Martins |
author_facet |
Andalécio, Mariana Martins Andrade, Rodrigo Soares de Lima, Luisa Carolina Santos Carvalho, Thiago de Amorim Silva, Ivania Aparecida Pimenta Santos |
author_role |
author |
author2 |
Andrade, Rodrigo Soares de Lima, Luisa Carolina Santos Carvalho, Thiago de Amorim Silva, Ivania Aparecida Pimenta Santos |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Andalécio, Mariana Martins Andrade, Rodrigo Soares de Lima, Luisa Carolina Santos Carvalho, Thiago de Amorim Silva, Ivania Aparecida Pimenta Santos |
dc.subject.por.fl_str_mv |
Parálisis Facial Simetria Toxina botulínica Assimetria. Facial Palsy Botulinum Toxin Symmetry Asymmetry. Paralisia Facial Toxina Botulínica Simetria Assimetria. |
topic |
Parálisis Facial Simetria Toxina botulínica Assimetria. Facial Palsy Botulinum Toxin Symmetry Asymmetry. Paralisia Facial Toxina Botulínica Simetria Assimetria. |
description |
Peripheral Facial Palsy (PFP) is a state of paralysis or weakening of the facial muscles that causes motor and aesthetic limitations to the patient with this condition. One means of treatment for PFP that is gaining prominence is the use of botulinum toxin on the side contralateral to that affected by the condition. This toxin is collected from the spores of the bacterium Clostridium botulinum, and its action inhibits the release of acetylcholine at the neuromuscular junction, reducing muscle hyperfunction and restoring symmetry to the patient's face. Therefore, this study aims to achieve the knowledge of the best protocol for the application of the toxin in paralysis, as well as which serotype to use and the ability to improve the patient's quality of life. The study consists of a basic, qualitative, descriptive-exploratory integrative review based on the main research platforms searching for the terms facial paralysis and botulinum toxin. Articles were included from 2011 to 2021 in the English language and the search resulted in 17 articles. In all reviewed articles the botulinum toxin serotype A was the only one used for the treatment, the amount of biological units (BIU) and the protocol was individualized for each patient exempting from a standard. The quality of life of the patients was restored after an improvement in facial symmetry was obtained and, with this, an increase in self-esteem, besides, mainly, restoring the ability to perform coordinated muscular actions. Therefore, it can be concluded that the treatment of PFP with botulinum toxin is highly beneficial to patients. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-07-21 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/17935 10.33448/rsd-v10i9.17935 |
url |
https://rsdjournal.org/index.php/rsd/article/view/17935 |
identifier_str_mv |
10.33448/rsd-v10i9.17935 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/17935/15921 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 9; e8510917935 Research, Society and Development; Vol. 10 Núm. 9; e8510917935 Research, Society and Development; v. 10 n. 9; e8510917935 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052683809456128 |